HemaMax™, a Recombinant Human Interleukin-12, Is a Potent Mitigator of Acute Radiation Injury in Mice and Non-Human Primates
Open Access
- 24 February 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (2), e30434
- https://doi.org/10.1371/journal.pone.0030434
Abstract
HemaMax, a recombinant human interleukin-12 (IL-12), is under development to address an unmet medical need for effective treatments against acute radiation syndrome due to radiological terrorism or accident when administered at least 24 hours after radiation exposure. This study investigated pharmacokinetics, pharmacodynamics, and efficacy of m-HemaMax (recombinant murine IL-12), and HemaMax to increase survival after total body irradiation (TBI) in mice and rhesus monkeys, respectively, with no supportive care. In mice, m-HemaMax at an optimal 20 ng/mouse dose significantly increased percent survival and survival time when administered 24 hours after TBI between 8–9 Gy (p50/30) significantly increased percent survival of HemaMax groups compared to vehicle (p<0.05 Pearson's chi-square test). This survival benefit was accompanied by a significantly higher leukocyte (neutrophils and lymphocytes), thrombocyte, and reticulocyte counts during nadir (days 12–14) and significantly less weight loss at day 12 compared to vehicle. These findings indicate successful interspecies dose conversion and provide proof of concept that HemaMax increases survival in irradiated rhesus monkeys by promoting hematopoiesis and recovery of immune functions and possibly gastrointestinal functions, likely through a network of interactions involving dendritic cells, osteoblasts, and soluble factors such as IL-12, IFN-γ, and cytoprotectant erythropoietin.Keywords
This publication has 86 references indexed in Scilit:
- Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibitionJCI Insight, 2010
- Trans-presentation: A novel mechanism regulating IL-15 delivery and responsesImmunology Letters, 2010
- A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignanciesMolecular Cancer Therapeutics, 2009
- Restoration and reversible expansion of the osteoblastic hematopoietic stem cell niche after marrow radioablationBlood, 2009
- Pro-Inflammatory Cytokine-Mediated Anemia: Regarding Molecular Mechanisms of ErythropoiesisMediators of Inflammation, 2009
- Multilineage hematopoietic recovery with concomitant antitumor effects using low dose Interleukin-12 in myelosuppressed tumor-bearing miceJournal of Translational Medicine, 2008
- Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcomaBlood, 2007
- Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinomaJournal of Translational Medicine, 2007
- Identification of stem cells in small intestine and colon by marker gene Lgr5Nature, 2007
- Emerging biological roles for erythropoietin in the nervous systemNature Reviews Neuroscience, 2005